Riskpilot← Back to searchSign inGet full accessShyan Medicine AB
ABIn liquidationOrg 5567802508Blåklocksvägen 59General medical practice activities · NACE 8621Est. 20091 employees
Revenue 2025
SEK 10,3M
-61% vs 2024
EBITDA margin
-2.3%
-319% vs 2024
Equity ratio
29.9%
Financial strength
Net profit 2025
SEK -239K
-636% vs 2024
| Revenue | SEK 10,3M | -61% |
| EBITDA | SEK -239K | -319% |
| Net profit | SEK -239K | -636% |
| Total assets | SEK 300K | -40% |
| Equity | SEK 90K | -82% |
| Employees | 1 | — |
Legal name
Shyan Medicine AB
Org number
5567802508
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
1 april 2009
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget ska bedriva medicinsk verksamhet med uthyrning av sjukvårdspersonal, förvaltning av aktier och fastigheter samt därmed förenlig verksamhet.
Address
Blåklocksvägen 59
Email
per@startabolag.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 46 106 | 4 014 | 9 845 | 26 250 | 10 259 |
| Staff expenses | — | −0 | — | — | — |
| EBITDA | −255 | 97 | −60 | −57 | −239 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | −255 | 97 | −60 | −57 | −239 |
| Net financials | −1 | −1 | 2 | 1 | 0 |
| Profit before tax | 1 | 72 | −8 | −32 | −239 |
| Tax | −2 | −16 | — | — | — |
| Net profit | −1 | 56 | −8 | −32 | −239 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 153 | 1 012 | 773 | 499 | 300 |
| Equity | 1 055 | 924 | 726 | 488 | 90 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 48 | 13 | 23 | 10 | 210 |
| Total debt | 48 | 13 | 23 | 10 | 210 |
EBITDA margin
-2.3%
This company
15.8%
Market median
-115% vs market
20212025
Equity ratio
29.9%
This company
38.2%
Market median
-22% vs market
20212025
Return on equity
-266.2%
This company
18.4%
Market median
-1547% vs market
20212025
Net profit margin
-2.3%
This company
8.1%
Market median
-128% vs market
20212025
Asset turnover
34.22×
This company
1.12×
Market median
+2955% vs market
20212025
Debt / equity
2.34×
This company
0.62×
Market median
-277% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PD Liquidator | Liquidator | 2026 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Deputy Board Member | 2022 – 2026 | |
| Board of Directors | 2022 – 2026 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Shyan Medicine AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Daniel Englund Rydberg | Liquidator | 0 companies |
| Gerd K Birgitta Sujeebun Olofsson | Deputy Board Member | 0 companies |
| Shyan Sujeebun | Board of Directors | 0 companies |